FDA 483 - Tripak Pharmaceuticals Pty Ltd - July 25, 2025

Tripak Pharmaceuticals Pty Ltd in Capalaba, Australia, received a Form 483 with nine observations following an FDA inspection. The observations highlight significant deficiencies in quality control, raw material testing, process validation, finished product release testing, stability programs, hold time studies, laboratory controls, equipment labeling, and labeling storage. These issues indicate a systemic failure to ensure drug product quality, identity, strength, and purity, potentially compromising patient safety for products shipped to the US market.